A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2018
At a glance
- Drugs Ribociclib (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Jun 2018 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
- 20 Jun 2018 Planned primary completion date changed from 1 May 2020 to 1 Jun 2020.